相关实验视频

Updated: Jul 29, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

一个系统的文献审查的MTAP删除在固体和血液癌症的癌症

Mary C Clouser¹, Mina Suh², Naimisha Movva²

¹Amgen, Thousand Oaks, CA, USA.

Cancer treatment and research communications

|July 29, 2025

概括

甲基氨酸酸化酶 (MTAP) 缺乏在许多癌症中被发现,显示出作为泛癌症治疗点的潜力. 本综述详细介绍了MTAP损失的患病率及其对各种癌症类型的预后影响.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症基因组学癌症基因组学

背景情况:

甲基氨酸酸化酶 (MTAP) 缺乏在许多癌症中很普遍.
MTAP状态是合成致命性策略的新兴生物标志物,特别是与PRMT5抑制.
了解MTAP的变化对于开发新的泛癌疗法至关重要.

研究的目的:

系统地审查有关成人和儿科固体和血液癌症中MTAP删除或表达损失的文献.
总结MTAP变化的患病率和预后影响.
确定MTAP作为潜在的泛癌治疗点.

主要方法:

系统的文献审查遵循PRISMA方法.
包括报告不同癌症类型中MTAP删除或损失的研究.
综合有关患病率,实验室检测,患者特征和临床结果的数据.

主要成果:

从352项初步研究中,确定了37项报告MTAP的研究.
下一代测序 (NGS) 是最常用的测试方法.
根据瘤类型,MTAP删除的患病率有很大差异,从胃癌的4%-14%到质母细胞瘤的26-60%.
删除MTAP与KRAS突变的更高患病率有关.
有证据表明,MTAP缺失患者的整体存活率可能会更差,特别是在GBM和NSCLC中,尽管研究结果异构.

结论:

这是第一个系统性审查,将各种癌症类型中MTAP删除/损失的发现整合起来.
在许多癌症中,MTAP的删除和/或表达的丧失是常见的.
对于开发泛癌疗法来说,MTAP的改变是一个有希望的目标.

关键词:

这就是CDKN2A.癌症癌症癌症癌症共同突变是一种共同突变.同卵同胞的删除.在MTAP中,MTAP是MTAP.幸存的生存方式

更多相关视频

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.